Cereno Scientific publishes annual report for 2020 on the company’s website and confirms digital AGM

 Cereno Scientific today announced that the annual report for 2020 is published on the company’s website, www.cerenoscientific.com. The company’s Board have also resolved that the annual general meeting 2021 will be held digitally due to covid-19. 

Cereno’s annual report for 2020 is available on the company’s website, both in Swedish and in English.

The annual general meeting (AGM) will be held exclusively digitally, with the support of the temporary rules that apply during the current covid-19 pandemic. Participation in the AGM will take place by using a digital postal voting form. Notice and other documents related to the AGM on June 9, 2021 will be available on the company's website no later than two weeks prior.

For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.